Cholangitis resident survival guide: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}}; {{AE}} {{VR}}
==Definition==
Acute cholangitis is a morbid condition characterized by the acute infection and inflammation of an obstructed [[bile duct]].<ref name="Kimura-2007">{{Cite journal  | last1 = Kimura | first1 = Y. | last2 = Takada | first2 = T. | last3 = Kawarada | first3 = Y. | last4 = Nimura | first4 = Y. | last5 = Hirata | first5 = K. | last6 = Sekimoto | first6 = M. | last7 = Yoshida | first7 = M. | last8 = Mayumi | first8 = T. | last9 = Wada | first9 = K. | title = Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 15-26 | month =  | year = 2007 | doi = 10.1007/s00534-006-1152-y | PMID = 17252293 }}</ref>
==Causes==
===Life Threatening Causes===
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.  Cholangitis can be a life-threatening condition if it becomes suppurative and it must be treated as such irrespective of the causes.<ref name="Kimura-2007">{{Cite journal  | last1 = Kimura | first1 = Y. | last2 = Takada | first2 = T. | last3 = Kawarada | first3 = Y. | last4 = Nimura | first4 = Y. | last5 = Hirata | first5 = K. | last6 = Sekimoto | first6 = M. | last7 = Yoshida | first7 = M. | last8 = Mayumi | first8 = T. | last9 = Wada | first9 = K. | title = Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 15-26 | month =  | year = 2007 | doi = 10.1007/s00534-006-1152-y | PMID = 17252293 }}</ref>
===Common Causes===
*[[Cholecystolithiasis]]
*[[Ampulla of Vater|Ampullary tumor]]
*[[Bile duct tumor]]
*[[Gallbladder tumor]]
*[[Pancreatic tumor]]<ref name="Lipsett-1990">{{Cite journal  | last1 = Lipsett | first1 = PA. | last2 = Pitt | first2 = HA. | title = Acute cholangitis. | journal = Surg Clin North Am | volume = 70 | issue = 6 | pages = 1297-312 | month = Dec | year = 1990 | doi =  | PMID = 2247816 }}</ref>
==Management==
Shown below is a diagram depicting the management of cholangitis according to the Society for Surgery of the Alimentary Tract (SSAT)<ref name="Duncan-2012">{{Cite journal  | last1 = Duncan | first1 = CB. | last2 = Riall | first2 = TS. | title = Evidence-based current surgical practice: calculous gallbladder disease. | journal = J Gastrointest Surg | volume = 16 | issue = 11 | pages = 2011-25 | month = Nov | year = 2012 | doi = 10.1007/s11605-012-2024-1 | PMID = 22986769 }}</ref> and Tokyo guidelines for management of cholangitis.<ref name="Mayumi-2013">{{Cite journal  | last1 = Mayumi | first1 = T. | last2 = Someya | first2 = K. | last3 = Ootubo | first3 = H. | last4 = Takama | first4 = T. | last5 = Kido | first5 = T. | last6 = Kamezaki | first6 = F. | last7 = Yoshida | first7 = M. | last8 = Takada | first8 = T. | title = Progression of Tokyo Guidelines and Japanese Guidelines for management of acute cholangitis and cholecystitis. | journal = J UOEH | volume = 35 | issue = 4 | pages = 249-57 | month = Dec | year = 2013 | doi =  | PMID = 24334691 }}</ref>
{{familytree/start |summary=Cholangitis}}
{{familytree | | | | | | | | | | | | | | | | | A01 | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Characterize the symptoms:''' <br> ❑ RUQ abdominal pain <br> ❑ Intermittent fever &/or chills<br> ❑ Jaundice<br> ❑ Lethargy or confusion </div> }}
{{familytree | | | | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | | | | B01 | |B01=<div style="float: left; text-align: left; line-height: 150% ">'''Examine the patient:'''<BR>❑ Altered mental status<BR>❑ Febrile<BR>❑ Dehydrated<BR>❑ Jaundice<BR>❑ Hypotension<BR>❑ Tachycardia<BR>❑ Dyspnea<BR>❑ Hypoxemia<BR>❑ Abdominal tenderness</div>}}
{{familytree | | | | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | | | | C01 | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Order laboratory tests:'''<br>❑ CBC<br>❑ BMP<br>❑ CRP<br>❑ Total bilirubin<br>❑ Direct bilirubin<br>❑ Albumin<br>❑ AST<br>❑ ALT<br>❑ Alkaline phosphatase<br>❑ GGT<br>❑ Amylase<br>❑ Lipase</div>}}
{{familytree | | | | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | | | | D01 | | |D01=<div style="float: left; text-align: left; line-height: 150% ">'''[[Cholangitis overview#Diagnostic criteria|Diagnostic criteria:]]'''<ref name="Mayumi-2013">{{Cite journal  | last1 = Mayumi | first1 = T. | last2 = Someya | first2 = K. | last3 = Ootubo | first3 = H. | last4 = Takama | first4 = T. | last5 = Kido | first5 = T. | last6 = Kamezaki | first6 = F. | last7 = Yoshida | first7 = M. | last8 = Takada | first8 = T. | title = Progression of Tokyo Guidelines and Japanese Guidelines for management of acute cholangitis and cholecystitis. | journal = J UOEH | volume = 35 | issue = 4 | pages = 249-57 | month = Dec | year = 2013 | doi =  | PMID = 24334691 }}</ref><br>❑ Systemic inflammation<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Fever >38℃ and/or shaking chills
:❑ WBC <4000/μl or >10000/μl and/or CRP ≥1 mg/dl</div></div><br>❑ Cholestasis<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Jaundice
:❑ Total bilirubin ≥2 g/dl
:❑ ALP (IU) >1.5×STD
:❑ GGT (IU) >1.5×STD
:❑ AST (IU) >1.5×STD
:❑ ALT (IU) >1.5×STD</div></div><br>❑ Imaging<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Evidence of the etiology on imaging (stricture, stone, stent etc.)</div></div></div>}}
{{familytree | | | | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | | | | E01 | | |E01=<div style="float: left; text-align: left; line-height: 150% "><BR>❑ Hospital admission<BR>❑ NPO<br>❑ IVF & correct electrolyte abnormalities<br>❑ Blood C&S<br>❑ Empiric IV antibiotics<ref name="Solomkin-2003">{{Cite journal  | last1 = Solomkin | first1 = JS. | last2 = Mazuski | first2 = JE. | last3 = Baron | first3 = EJ. | last4 = Sawyer | first4 = RG. | last5 = Nathens | first5 = AB. | last6 = DiPiro | first6 = JT. | last7 = Buchman | first7 = T. | last8 = Dellinger | first8 = EP. | last9 = Jernigan | first9 = J. | title = Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. | journal = Clin Infect Dis | volume = 37 | issue = 8 | pages = 997-1005 | month = Oct | year = 2003 | doi = 10.1086/378702 | PMID = 14523762 }}</ref><div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Ceftriaxone 1 g IV every 24 hours or 2 g IV every 12 hours for CNS infections + Metronidazole 500 mg IV every 8 hours
'''or'''
:❑ Ciprofloxacin 400 mg IV every 12 hours/Levofloxacin 500 or 750 mg IV once daily + Metronidazole 500 mg IV every 8 hours</div></div><br>❑ Acute pain management<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Ketorolac 30-60 mg IM/IV single dose
'''or'''
:❑ Opioids until drainage or surgical intervention if ketorolac is contraindicated/pain not improving</div></div><br>❑ [[Cholangitis overview#Severity Assessment Criteria|Assess severity]]<ref name="Mayumi-2013">{{Cite journal  | last1 = Mayumi | first1 = T. | last2 = Someya | first2 = K. | last3 = Ootubo | first3 = H. | last4 = Takama | first4 = T. | last5 = Kido | first5 = T. | last6 = Kamezaki | first6 = F. | last7 = Yoshida | first7 = M. | last8 = Takada | first8 = T. | title = Progression of Tokyo Guidelines and Japanese Guidelines for management of acute cholangitis and cholecystitis. | journal = J UOEH | volume = 35 | issue = 4 | pages = 249-57 | month = Dec | year = 2013 | doi =  | PMID = 24334691 }}</ref></div>}}
{{familytree | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | |}}
{{familytree | | | | | | | | | | | F01 | | | | F02 | | | | F03 | | |F01=Grade 1 (Mild)|F02= Grade 2 (Moderate)|F03= Grade 3 (Severe)}}
{{familytree | | | | | | | | | | | |!| | | | | |!| | | | | |!| | |}}
{{familytree | | | | | | | | | | | G01 | | | | G02 | | | | G03 | |G01=<div style="float: left; text-align: left; line-height: 150% ">❑ NPO<br>❑ IVF & correct electrolyte abnormalities<br>❑ IV antibiotics (full dose)<br>❑ IV pain management w/ analgesics<br>❑ [[Cholangitis overview#Severity Assessment Criteria|Severity assessment]]<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Within 24 hours after diagnosis (every 6-12 hours)
:❑ During the time zone of 24-48 hours (every 6-12 hours)</div></div></div>|G02=<div style="float: left; text-align: left; line-height: 150% ">❑ NPO<br>❑ IVF & correct electrolyte abnormalities<br>❑ IV antibiotics (full dose)<br>❑ IV pain management w/ analgesics<br>❑ [[Cholangitis overview#Severity Assessment Criteria|Severity assessment]]<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Within 24 hours after diagnosis (every 6-12 hours)
:❑ During the time zone of 24-48 hours (every 6-12 hours)</div></div><br>❑ Immediate biliary tract drainage within 24-48 hours</div>|G03=<div style="float: left; text-align: left; line-height: 150% ">❑ NPO<br>❑ IVF & correct electrolyte abnormalities<br>❑ IV antibiotics (full dose)<br>❑ IV pain management w/ analgesics<br>❑ [[Cholangitis overview#Severity Assessment Criteria|Severity assessment]]<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ Within 24 hours after diagnosis (every 6-12 hours)
:❑ During the time zone of 24-48 hours (every 6-12 hours)</div></div><br>❑ Immediate organ support<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed">
:❑ NIPPV/ IPPV
:❑ Vasopressors</div></div><br>❑ Urgent biliary tract drainage</div>}}
{{familytree | | | | | | | | | |,|-|^|-|.| | | |!| | | | | |!| |}}
{{familytree | | | | | | | | | H01 | | H02 | | |!| | | | | |!| |H01=Improvement|H02=No improvement within the first 24 hours}}
{{familytree | | | | | | | | | |!| | | |!| | | |!| | | | | |!| |}}
{{familytree | | | | | | | | | I01 | | I02 | | |!| | | | | |!| |I01=Finish antibiotic course|I02=Immediate biliary tract drainage within 24 hours}}
{{familytree | | | | | | | | | |`|-|-|-|^|-|v|-|^|-|-|-|-|-|'| |}}
{{familytree | | | | | | | | | | | | | | | J01 | | | | | | |J01=Treatment for etiology if still needed (endoscopic treatment, percutaneous treatment, or operative intervention)}}
{{familytree/end}}
<sup>†</sup>ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMP: Basic Metabolic Profile; CBC: Complete Blood Count; CBD: Common Bile Duct; CRP: C-reactive protein; ERCP: Endoscopic retrograde cholangiopancreatography; C&S: Culture & Sensitivity; GGT: Gamma-glutamyl transpeptidase; IM: Intramuscular; IPPV: Invasive Positive Pressure Ventilation; IV: Intravenous; IVF: Intravenous fluids; NIPPV: Non Invasive Positive Pressure Ventilation; NPO: Nil Per Oral; RUQ: Right Upper Quadrant; WBC: White Blood Cell; W/: With
==Do's==
* Perform blood cultures in all patients with suspicion or diagnosis of [[cholangitis]] in order to direct the antibiotic therapy.
* Biliary drainage is done with [[ERCP]], which is the gold standard for both diagnosis and treatment of acute cholangitis.<ref name="Agarwal-2006">{{Cite journal  | last1 = Agarwal | first1 = N. | last2 = Sharma | first2 = BC. | last3 = Sarin | first3 = SK. | title = Endoscopic management of acute cholangitis in elderly patients. | journal = World J Gastroenterol | volume = 12 | issue = 40 | pages = 6551-5 | month = Oct | year = 2006 | doi =  | PMID = 17072990 }}</ref>  It is preferred over both surgical and percutaneous biliary drainage.<ref name="Lee-2009">{{Cite journal  | last1 = Lee | first1 = JG. | title = Diagnosis and management of acute cholangitis. | journal = Nat Rev Gastroenterol Hepatol | volume = 6 | issue = 9 | pages = 533-41 | month = Sep | year = 2009 | doi = 10.1038/nrgastro.2009.126 | PMID = 19652653 }}</ref>
* Consider transferring the patient with grade 2 (moderate) and grade 3 (severe) severity to another hospital if immediate (within 24-48 hours) or urgent biliary tract drainage cannot be performed due to the lack of facilities or skilled personnel.
* Obtain cultures from bile or stents removed at ERCP for grade II (moderate) and III (severe) patients.
* [[Cholecystectomy]] should be performed for [[cholecystolithiasis]] after acute cholangitis has resolved.
* If ERCP drainage is not possible, percutaneous transhepatic biliary drainage or surgical decompression with CBD exploration and stone removal are the alternate options.
* Consider the placement of a T-tube drainage that allows biliary access for stone removal if the patient is unstable and stone removal is not possible.
* For large impacted stones where [[ERCP]], percutaneous methods, and/or operative interventions are not possible, choledochoduodenostomy or choledochojejunostomy may be necessary.
==Dont's==
Occlusive cholangiography should not be performed in patients with acute cholangitis since it can lead to the development of [[septicemia]].
==References==
{{Reflist|2}}
[[Category:Help]]
[[Category:Projects]]
[[Category:Resident survival guide]]
[[Category:Templates]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 16:22, 21 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]

Definition

Acute cholangitis is a morbid condition characterized by the acute infection and inflammation of an obstructed bile duct.[1]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Cholangitis can be a life-threatening condition if it becomes suppurative and it must be treated as such irrespective of the causes.[1]

Common Causes

Management

Shown below is a diagram depicting the management of cholangitis according to the Society for Surgery of the Alimentary Tract (SSAT)[3] and Tokyo guidelines for management of cholangitis.[4]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ RUQ abdominal pain
❑ Intermittent fever &/or chills
❑ Jaundice
❑ Lethargy or confusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Altered mental status
❑ Febrile
❑ Dehydrated
❑ Jaundice
❑ Hypotension
❑ Tachycardia
❑ Dyspnea
❑ Hypoxemia
❑ Abdominal tenderness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order laboratory tests:
❑ CBC
❑ BMP
❑ CRP
❑ Total bilirubin
❑ Direct bilirubin
❑ Albumin
❑ AST
❑ ALT
❑ Alkaline phosphatase
❑ GGT
❑ Amylase
❑ Lipase
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic criteria:[4]
❑ Systemic inflammation
❑ Fever >38℃ and/or shaking chills
❑ WBC <4000/μl or >10000/μl and/or CRP ≥1 mg/dl

❑ Cholestasis
❑ Jaundice
❑ Total bilirubin ≥2 g/dl
❑ ALP (IU) >1.5×STD
❑ GGT (IU) >1.5×STD
❑ AST (IU) >1.5×STD
❑ ALT (IU) >1.5×STD

❑ Imaging
❑ Evidence of the etiology on imaging (stricture, stone, stent etc.)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Hospital admission
❑ NPO
❑ IVF & correct electrolyte abnormalities
❑ Blood C&S
❑ Empiric IV antibiotics[5]
❑ Ceftriaxone 1 g IV every 24 hours or 2 g IV every 12 hours for CNS infections + Metronidazole 500 mg IV every 8 hours

or

❑ Ciprofloxacin 400 mg IV every 12 hours/Levofloxacin 500 or 750 mg IV once daily + Metronidazole 500 mg IV every 8 hours

❑ Acute pain management
❑ Ketorolac 30-60 mg IM/IV single dose

or

❑ Opioids until drainage or surgical intervention if ketorolac is contraindicated/pain not improving

Assess severity[4]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grade 1 (Mild)
 
 
 
Grade 2 (Moderate)
 
 
 
Grade 3 (Severe)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ NPO
❑ IVF & correct electrolyte abnormalities
❑ IV antibiotics (full dose)
❑ IV pain management w/ analgesics
Severity assessment
❑ Within 24 hours after diagnosis (every 6-12 hours)
❑ During the time zone of 24-48 hours (every 6-12 hours)
 
 
 
❑ NPO
❑ IVF & correct electrolyte abnormalities
❑ IV antibiotics (full dose)
❑ IV pain management w/ analgesics
Severity assessment
❑ Within 24 hours after diagnosis (every 6-12 hours)
❑ During the time zone of 24-48 hours (every 6-12 hours)

❑ Immediate biliary tract drainage within 24-48 hours
 
 
 
❑ NPO
❑ IVF & correct electrolyte abnormalities
❑ IV antibiotics (full dose)
❑ IV pain management w/ analgesics
Severity assessment
❑ Within 24 hours after diagnosis (every 6-12 hours)
❑ During the time zone of 24-48 hours (every 6-12 hours)

❑ Immediate organ support
❑ NIPPV/ IPPV
❑ Vasopressors

❑ Urgent biliary tract drainage
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement
 
No improvement within the first 24 hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finish antibiotic course
 
Immediate biliary tract drainage within 24 hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment for etiology if still needed (endoscopic treatment, percutaneous treatment, or operative intervention)
 
 
 
 
 
 

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMP: Basic Metabolic Profile; CBC: Complete Blood Count; CBD: Common Bile Duct; CRP: C-reactive protein; ERCP: Endoscopic retrograde cholangiopancreatography; C&S: Culture & Sensitivity; GGT: Gamma-glutamyl transpeptidase; IM: Intramuscular; IPPV: Invasive Positive Pressure Ventilation; IV: Intravenous; IVF: Intravenous fluids; NIPPV: Non Invasive Positive Pressure Ventilation; NPO: Nil Per Oral; RUQ: Right Upper Quadrant; WBC: White Blood Cell; W/: With

Do's

  • Perform blood cultures in all patients with suspicion or diagnosis of cholangitis in order to direct the antibiotic therapy.
  • Biliary drainage is done with ERCP, which is the gold standard for both diagnosis and treatment of acute cholangitis.[6] It is preferred over both surgical and percutaneous biliary drainage.[7]
  • Consider transferring the patient with grade 2 (moderate) and grade 3 (severe) severity to another hospital if immediate (within 24-48 hours) or urgent biliary tract drainage cannot be performed due to the lack of facilities or skilled personnel.
  • Obtain cultures from bile or stents removed at ERCP for grade II (moderate) and III (severe) patients.
  • Cholecystectomy should be performed for cholecystolithiasis after acute cholangitis has resolved.
  • If ERCP drainage is not possible, percutaneous transhepatic biliary drainage or surgical decompression with CBD exploration and stone removal are the alternate options.
  • Consider the placement of a T-tube drainage that allows biliary access for stone removal if the patient is unstable and stone removal is not possible.
  • For large impacted stones where ERCP, percutaneous methods, and/or operative interventions are not possible, choledochoduodenostomy or choledochojejunostomy may be necessary.

Dont's

Occlusive cholangiography should not be performed in patients with acute cholangitis since it can lead to the development of septicemia.

References

  1. 1.0 1.1 Kimura, Y.; Takada, T.; Kawarada, Y.; Nimura, Y.; Hirata, K.; Sekimoto, M.; Yoshida, M.; Mayumi, T.; Wada, K. (2007). "Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines". J Hepatobiliary Pancreat Surg. 14 (1): 15–26. doi:10.1007/s00534-006-1152-y. PMID 17252293.
  2. Lipsett, PA.; Pitt, HA. (1990). "Acute cholangitis". Surg Clin North Am. 70 (6): 1297–312. PMID 2247816. Unknown parameter |month= ignored (help)
  3. Duncan, CB.; Riall, TS. (2012). "Evidence-based current surgical practice: calculous gallbladder disease". J Gastrointest Surg. 16 (11): 2011–25. doi:10.1007/s11605-012-2024-1. PMID 22986769. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 4.2 Mayumi, T.; Someya, K.; Ootubo, H.; Takama, T.; Kido, T.; Kamezaki, F.; Yoshida, M.; Takada, T. (2013). "Progression of Tokyo Guidelines and Japanese Guidelines for management of acute cholangitis and cholecystitis". J UOEH. 35 (4): 249–57. PMID 24334691. Unknown parameter |month= ignored (help)
  5. Solomkin, JS.; Mazuski, JE.; Baron, EJ.; Sawyer, RG.; Nathens, AB.; DiPiro, JT.; Buchman, T.; Dellinger, EP.; Jernigan, J. (2003). "Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections". Clin Infect Dis. 37 (8): 997–1005. doi:10.1086/378702. PMID 14523762. Unknown parameter |month= ignored (help)
  6. Agarwal, N.; Sharma, BC.; Sarin, SK. (2006). "Endoscopic management of acute cholangitis in elderly patients". World J Gastroenterol. 12 (40): 6551–5. PMID 17072990. Unknown parameter |month= ignored (help)
  7. Lee, JG. (2009). "Diagnosis and management of acute cholangitis". Nat Rev Gastroenterol Hepatol. 6 (9): 533–41. doi:10.1038/nrgastro.2009.126. PMID 19652653. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources